Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2025-03-04 Legal Proceedings Report
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BIOS_PR_20250304_EN.pdf
Legal Proceedings Report Classification · 100% confidence The document is a press release issued by BioSenic regarding the judicial liquidation of its subsidiary, Medsenic. It discusses the financial impact of this event, ongoing debt restructuring negotiations, and the status of its financing programs. Since this is a corporate announcement regarding significant business developments and financial status, but does not fit into specific categories like 'Legal Proceedings' (which usually refers to litigation) or 'M&A' (which refers to mergers/acquisitions), it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-03-04 English
BIOS_PR_20250304_FR.pdf
Legal Proceedings Report Classification · 100% confidence The document is a press release from BioSenic regarding the liquidation of its subsidiary, Medsenic. It discusses the financial impact of this event, ongoing debt restructuring negotiations, and updates on financing programs. While it touches on financial matters, it is a corporate announcement regarding a significant business event (subsidiary liquidation) rather than a periodic financial report, audit, or proxy statement. Given the nature of the announcement as a regulatory disclosure of material information, it fits best under the 'Regulatory Filings' category.
2025-03-04 French
BIOS_PR_20250304_EN.pdf
Legal Proceedings Report Classification · 99% confidence The document is a press release dated March 4, 2025, announcing that the subsidiary Medsenic has been admitted to judicial liquidation following a declaration of cessation of payment. It discusses the financial impacts (impairment, unrecovered receivable) and ongoing negotiations with creditors regarding debt restructuring and financing tranches. This type of announcement, detailing significant corporate events, financial distress, and operational changes outside of routine periodic financial reporting (like 10-K or IR), is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) due to the debt restructuring focus. However, since it is a specific, material, non-scheduled corporate event announcement that doesn't fit the other specific categories (like DIRS, DIV, ER, etc.), RNS serves as the most appropriate general regulatory announcement category, as per the definitions provided, especially since it references prior press releases. Given the content focuses heavily on debt restructuring negotiations and liquidity conditions, 'CAP' (Capital/Financing Update) is also a strong candidate. However, the primary trigger is the judicial liquidation, which is a major corporate event announcement. I will classify it as RNS as it is a material, unscheduled regulatory announcement that doesn't fit the more specific financial report types.
2025-03-04 English
BIOS_PR_20250304_FR.pdf
Legal Proceedings Report Classification · 99% confidence The document is a press release dated March 4, 2025, announcing that the subsidiary Medsenic has been admitted to judicial liquidation following a declaration of cessation of payments. It discusses the expected financial impacts (impairment, unrecovered debt) and ongoing negotiations with creditors regarding debt restructuring and financing programs (convertible bonds). The header explicitly labels it as 'COMMUNIQUE DE PRESSE – INFORMATION PRIVILÉGIÉE 4/03/2025'. This type of announcement, detailing significant corporate events, financial distress, and ongoing financing/restructuring efforts, fits best under the 'Capital/Financing Update' (CAP) category, as it directly addresses debt restructuring and the continuation of financing activities despite the subsidiary's failure. While it touches on legal matters (liquidation), the primary focus is the financial and capital structure implications. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard regulatory filing (RNS) that doesn't fit elsewhere; it is a specific update on capital structure/financing distress.
2025-03-04 French
BIOS_PR_2025_February_Denominator_EN.pdf
Share Issue/Capital Change Classification · 100% confidence The document is a press release from BioSenic announcing an increase in the total number of voting rights and shares due to the issuance of new shares. It explicitly references Article 15 of the Belgian law regarding the publication of major shareholdings and capital changes. This type of disclosure, which details changes in share capital and voting rights, falls under the category of share issues and capital changes.
2025-02-27 English
BIOS_PR_2025_février_Denominator_FR.pdf
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory announcement from BioSenic regarding the total number of voting rights and shares, following the issuance of new shares. This type of disclosure is a standard requirement for listed companies to inform the market about changes in their capital structure and share count. It fits the definition of a 'Share Issue/Capital Change' (SHA) announcement, as it explicitly details the increase in shares and voting rights.
2025-02-27 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.